×
Incyte Common Stock Net 2010-2024 | INCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Incyte common stock net for the quarter ending September 30, 2024 was
$0.000B
, a
14.29% decline
year-over-year.
Incyte common stock net for 2023 was
$0B
, a
0.45% increase
from 2022.
Incyte common stock net for 2022 was
$0B
, a
0.9% increase
from 2021.
Incyte common stock net for 2021 was
$0B
, a
0.91% increase
from 2020.
View More
Incyte Common Stock Net 2010-2024 | INCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Incyte common stock net for 2023 was
$0B
, a
0.45% increase
from 2022.
Incyte common stock net for 2022 was
$0B
, a
0.9% increase
from 2021.
Incyte common stock net for 2021 was
$0B
, a
0.91% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.4B
Gilead Sciences (GILD)
$121.9B
Bristol Myers Squibb (BMY)
$111B
CSL (CSLLY)
$91.9B
Regeneron Pharmaceuticals (REGN)
$90.6B
GSK (GSK)
$76B
Argenex SE (ARGX)
$35.4B
Alnylam Pharmaceuticals (ALNY)
$35.1B
BioNTech SE (BNTX)
$25.7B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$24.6B
BeiGene (BGNE)
$20.1B
Moderna (MRNA)
$19.3B
Genmab (GMAB)
$15.3B
Insmed (INSM)
$12.8B
Vaxcyte (PCVX)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.5B
Exelixis (EXEL)
$10.2B
QIAGEN (QGEN)
$10.1B
Revolution Medicines (RVMD)
$9.9B
Exact Sciences (EXAS)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.1B
Ascendis Pharma (ASND)
$7.7B
Viking Therapeutics (VKTX)
$7.7B